From MIPS to MVPs to ASM: What Practices Need to Know Before 2027

Medicare’s quality reporting rules have shifted three times in less than a decade, and the pace isn’t slowing down. The path from MIPS to MVPs to ASM shows a steady move away from open-ended reporting and toward mandatory, condition-based accountability. For practices still adjusting to MIPS Value Pathways, the Ambulatory Specialty Model adds a new layer that changes who reports, what they report, and how much is riding on the outcome.

At Prime Well Med Solutions, we work with clinicians who are trying to figure out what this shift means for their next reporting year, their revenue, and their staffing. Here’s a look at how each program works, what’s changing under the CY 2026 Physician Fee Schedule final rule, and what to do about it now.

MIPS to MVPS to ASM: Traditional MIPS Gave Clinicians Room to Choose

The Merit-based Incentive Payment System launched in 2017 as a broad, self-directed program. Clinicians and groups picked six quality measures from a list of more than 200. They chose up to four improvement activities from over 100 options, and reported through whichever submission method fit their workflow. The submission methods being registry, EHR, claims, or a qualified clinical data registry.

That flexibility was the point. It let a small family practice and a large orthopedic group operate inside the same program without forcing either one into measures that had nothing to do with their patients. But flexibility came with a tradeoff.

Where Traditional MIPS Ran Into Trouble

A cardiologist could report on general preventive measures instead of anything tied to cardiac outcomes, and CMS had no reliable way to compare clinicians treating similar patients.

• Self-selected measures made cross-specialty comparison unreliable.
• Many measures became “topped out,” meaning nearly everyone scored well regardless of care quality.
• Quality scores often failed to correlate with cost or patient outcomes.

CMS flagged these gaps repeatedly, and that criticism set the stage for the next phase.

MIPS Value Pathways Brought Measures Into Alignment

MIPS Value Pathways, introduced in 2023, group measures around a clinical theme instead of leaving selection entirely open. A cardiology MVPs might include statin therapy for ASCVD alongside a patient-reported outcome measure like the Kansas City Cardiomyopathy Questionnaire. So scoring reflects the condition a clinician treats day to day.

Reporting under an MVPs typically involves six to nine quality measures, four to six pre-selected improvement activities, and at least one patient-reported outcome measure. Groups with more than one specialty can also report by subgroup, which keeps a multi-specialty practice from being judged as one undifferentiated block.

MVPs run on the same category weights as traditional MIPS, quality and cost each carry substantial weight, with improvement activities and Promoting Interoperability filling out the rest. But the measures inside those categories are tighter and more comparable across similar practices. CMS has also pushed MVPs reporting toward FHIR-based digital quality measures, with full transition targeted by 2028.

The Ambulatory Specialty Model Removes the Choice Entirely

CMS finalized the Ambulatory Specialty Model on October 31, 2025, as part of the CY 2026 Medicare Physician Fee Schedule final rule. Where MIPS offers options and MVPs offer curated sets, ASM offers neither. It’s a mandatory, two-sided risk model. And there’s no opt-out or hardship exemption for clinicians who meet the eligibility criteria in a selected geographic market.

ASM launches January 1, 2027, and runs for five performance years through 2031, with payment adjustments continuing into 2033. CMS expects to notify affected clinicians through a preliminary participant list in early 2026 followed by a final list mid-year. This is all based on prior billing data.

Who Falls Under ASM?

The model targets two high-cost, high-prevalence chronic conditions. Those are heart failure and low back pain. Physicians in the following specialties are within scope if they practice in a selected market:

• General cardiology
• Anesthesiology
• Neurosurgery
• Orthopedic surgery
• Pain management
• Physical medicine and rehabilitation

Estimates put total participation at roughly 8,600 physicians once selected regions are finalized, covering close to a quarter of eligible U.S. markets.

What Sets ASM Apart From MIPS and MVPs?

ASM strips away clinician discretion in every category that mattered under the earlier programs. CMS defines the measures, the reporting method, and the benchmark, and none of it can be substituted.

• Quality and cost measures are fixed by CMS and tied directly to heart failure or low back pain — no clinician selection.
• Reporting must happen through certified electronic methods; claims-based submission isn’t an option.
• Benchmarking compares clinicians only against peers managing the same condition, not against the entire MIPS population.
• Patient-reported outcomes, such as functional status and symptom improvement, directly affect payment.
• Payment adjustments can run as high as 9% or more in either direction depending on the performance year, and ASM does not count as an Advanced Alternative Payment Model, so it carries no bonus incentive.

CMS has described ASM as a proof of concept for future specialty payment models built around a single condition. If it performs as intended, similar condition-based programs for other specialties could follow.

Why This Progression Matters Right Now?

Each step in this progression narrows the gap between reporting and payment. Under MIPS, a low score cost a modest adjustment. Under an MVPs, the stakes rose slightly because measures aligned more directly with a clinician’s specialty. Under ASM, a poor outcome on a fixed set of condition-based measures translates almost immediately into a payment penalty, with no substitute measures to soften the blow.

Practices in the affected specialties — particularly cardiology, orthopedics, neurosurgery, pain management, anesthesiology, and physical medicine — should start preparing well before the 2027 performance year begins.

• Confirm whether your TIN/NPI combination falls within an eligible specialty and billing pattern.
• Review current CEHRT capabilities against the digital reporting requirements ASM demands.
• Build referral relationships and care-coordination workflows with primary care partners now, since ASM ties improvement activities to that kind of coordination.
• Start tracking patient-reported outcome data for heart failure or low back pain patients ahead of the mandatory reporting period.

Waiting for the final participant list before acting leaves very little runway to adjust workflows, train staff, and validate data pipelines.

How PWMS Supports MIPS Management Through the Transition?

Every program in this progression asks something different of a practice’s reporting infrastructure, and getting MIPS Management wrong at any stage can mean lost incentive dollars or an unexpected penalty. Prime Well Med Solutions works alongside practices at each phase of that transition, from a traditional MIPS submission this year to ASM readiness ahead of 2027.

• Measure selection and scoring projections tailored to a practice’s specialty and patient population.
• MVPs subgroup reporting support for multi-specialty groups.
• Readiness assessments that flag whether a TIN/NPI is likely to fall inside an ASM cohort.
• Workflow and CEHRT gap analysis to prepare for mandatory digital reporting.
• Ongoing tracking of patient-reported outcome measures, so data collection isn’t rushed once ASM reporting begins.

The move from MIPS to MVPs to ASM isn’t a single event — it’s a multi-year transition that rewards practices willing to prepare early and penalizes the ones that wait. Prime Well Med Solutions helps clinicians read the fine print in each CMS rule, adjust reporting strategy before deadlines hit, and walk into 2027 with a plan already in motion rather than a scramble already underway.